Gastro-Intestinal CoP

Hi All,

I am am posting to enquire whether any of your ambulatory chemotherapy services have any guidelines or protocols in place for the management of hypertension on treatment days for patients receiving Bevacizumab?

Our Chemotherapy Day Unit has been experiencing ongoing challenges with hypertension management in patients receiving Bevacizumab. This can result in patients occupying treatment chairs for two or more hours while awaiting a suitable blood pressure, leading to significant delays and subsequent “chair blocks” that impact patient flow throughout the remainder of the day, in addition to the extra emotional and physical burden placed on the patient.

We are particularly interested in whether your centre has established parameters regarding:
- When Bevacizumab treatment can safely proceed based on blood pressure
- What interventions can be undertaken by nursing staff (ie. GTN path/oral therapy if >SBP XX / >DBP XX)
- Appropriate timeframes for reassessment following interventions (ie. re-check 30 mins post, if SBP remains XX, escalate to XX)
- When treatment should be delayed or withheld
- When medical review or escalation is required

Our aim is to develop a clear and practical approach that allows hypertension to be managed safely and efficiently, while minimising prolonged chair occupancy and disruption to the chemotherapy schedule.

If your services have any guidelines, protocols, or resources that you would be willing to share, it would greatly appreciate it.

Thank you, and I look forward to hearing from you!

Created: 18 Aug 2026 10:08:39 AM